Moderate riskFDA DrugClass III

Novadoz Pharmaceuticals glycopyrrolate oral solution recalled for failed purity specifications

Novadoz Pharmaceuticals is recalling specific lots of glycopyrrolate oral solution (1 mg/5 mL) because the medication failed quality testing for impurities and degradation. The affected lots may not meet safety and effectiveness standards. Three lots are involved, with expiration dates between April and May 2027.

From the FDA notice · Read the official notice ↗

What to do

  1. Check your glycopyrrolate bottle for lot number CB2505159A, CB2505160A, or CB2505161A
  2. Do not use the medication if it matches one of these lots
  3. Contact your pharmacist or doctor for a replacement or alternative medication
  4. Return the recalled medication to your pharmacy

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Glycopyrrolate Oral Solution, 1 mg/5 mL, 16 oz. (473 mL), Rx only, Manufactured by: MSN Pharmaceuticals Inc., Piscataway, NJ 08854, Distributed by: Novadoz Pharmaceuticals LLC, Piscataway, NJ 08854, NDC 72205-070-72
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
20 Duke Rd Ste A, N/A, Piscataway, NJ, United States
Classification
Class III
Recall number
D-0300-2026

In the FDA's words

Description
Glycopyrrolate Oral Solution, 1 mg/5 mL, 16 oz. (473 mL), Rx only, Manufactured by: MSN Pharmaceuticals Inc., Piscataway, NJ 08854, Distributed by: Novadoz Pharmaceuticals LLC, Piscataway, NJ 08854, NDC 72205-070-72 Failed Impurities/Degradation Specifications Lot # CB2505159A, CB2505160A, Exp Date: 04/2027; Lot # CB2505161A, Exp Date: 05/2027 Distribution: US Nationwide. Affected quantity: N/A
Hazard
Failed Impurities/Degradation Specifications

Related topics

Industrial chemicalsOtherDrugsSold nationwideMore from FDA Drug